Huwel Lifesciences

What Huwel Lifesciences does

Huwel Lifesciences is a Hyderabad-based molecular diagnostics manufacturer that designs, develops, and manufactures indigenous infectious disease diagnostic products. The company was founded in 2015 and operates with a small team (11–50 employees) focused on RT-PCR kits, point-of-care nucleic acid amplification testing (NAAT) devices, and multi-target disease detection panels. Its portfolio of 100+ products spans tuberculosis, HIV, hepatitis, cervical cancer (HPV), sepsis, and antimicrobial resistance, with three flagship platforms: the Quantiplus MTB FAST tuberculosis diagnostic (priced at approximately ₹340 per sample versus ₹700–₹1,000 for incumbent systems), the UniAmp NAT near point-of-care device, and the Cubo ultra-compact RT-PCR platform launched in April 2026 for rural and mobile deployment.

Huwel monetises primarily through hardware and consumable sales to government healthcare programmes, public health institutions, and international health organisations. Its commercial motion combines direct institutional engagement with channel partnerships, most notably a strategic alliance with Avio Smart Market Stack Limited (ASMS, formerly Bartronics India), which holds up to a 30% equity stake (15% initial plus 15% option) for an investment of up to ₹50 crore and is entitled to a defined share of net project revenues secured through its institutional engagement efforts. The company also generates licensing and technology-transfer revenue through international expansion into Africa and Southeast Asia.

The regulatory profile is unusually strong for a company of its size: products carry ICMR approval, WHO procurement endorsements, and Health Technology Assessment validation, and the UniAmp NAT device is one of three platforms supported by the Stop TB Partnership's TB REACH Wave 11 Plus (US$2.7 million, 18 projects, 12 countries, ~150,000 tests expected in 2026). The company is led by founders Rachana Tripathi (CEO) and Shesheer Kumar (Managing Director), with Sandeep Pandya appointed in June 2026 to lead international sales expansion.

Name

Huwel Lifesciences

Legal name

Huwel Lifesciences

Website

https://huwellifesciences.in

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Huwel Lifesciences is a Hyderabad-based molecular diagnostics manufacturer that develops indigenous RT-PCR and point-of-care NAAT devices and kits for tuberculosis, HIV, hepatitis, HPV, sepsis, and antimicrobial resistance, serving Indian government healthcare programmes and international public health initiatives.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI)

Keywords

• Molecular diagnostics
• RT-PCR kits
• Infectious disease testing
• Point-of-care diagnostics
• Tuberculosis detection

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Molecular Diagnostic Products: Sale of RT-PCR diagnostic kits, point-of-care molecular testing devices, and disease detection panels for tuberculosis, HIV, hepatitis, cervical cancer, and other infectious diseases to healthcare institutions and government programs
2. Public Health Programme Diagnostics: Revenue from large-scale public tuberculosis diagnostics contracts through institutional engagement and government healthcare programme partnerships, with ASMS entitled to defined share of net project revenues
3. Licensing and Technology Transfer: International expansion into emerging markets like Africa and Southeast Asia through strategic partnerships and distribution agreements for indigenous healthcare technologies

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels2 records

Core offering

Huwel Lifesciences is a Hyderabad-based manufacturer of molecular diagnostic products, designing, developing, and manufacturing in-house RT-PCR kits, point-of-care molecular testing devices, and disease detection panels. Its portfolio of over 100 infectious disease diagnostic products covers tuberculosis, HIV, hepatitis, HPV/cervical cancer, sepsis, and antimicrobial resistance, with key offerings including the Quantiplus MTB FAST tuberculosis platform, the UniAmp NAT Device, and the Cubo ultra-compact RT-PCR platform. Products are ICMR-approved and certain devices are WHO-ordered, with pricing approximately ₹340 per sample versus ₹700–₹1,000 for competing molecular testing systems.

Product overview

Huwel Lifesciences is a Hyderabad-based molecular diagnostics company offering a comprehensive portfolio of indigenous diagnostic products. The core product offerings include the Quantiplus MTB FAST tuberculosis diagnostic platform, the UniAmp NAT Device for point-of-care nucleic acid amplification testing, and the recently launched Cubo ultra-compact RT-PCR platform. The company manufactures over 100 infectious disease diagnostic products covering tuberculosis, HIV, hepatitis, HPV/cervical cancer, sepsis, and antimicrobial resistance. Products are designed, developed, and manufactured in-house with capabilities spanning RT-PCR diagnostic kits, point-of-care molecular testing devices, and disease detection panels.

Differentiator

Problem solved

Functional benefit

Products and services

• Quantiplus MTB FAST Tuberculosis diagnostic platform offering molecular testing at approximately ₹340 per sample compared to ₹700–₹1,000 for existing molecular testing systems used in government programmes; received Health Technology Assessment validation.
• UniAmp NAT Device Point-of-care nucleic acid amplification test (NAAT) device for TB diagnosis, supported by Stop TB Partnership TB REACH Wave 11 Plus initiative with approximately 150,000 tests expected in 2026 across 12 countries.
• Cubo RT-PCR Platform Ultra-compact RT-PCR platform for point-of-care molecular diagnostics enabling laboratory-grade RT-PCR testing in a portable form factor for deployment in rural clinics, district hospitals, and mobile health units, supporting TB, respiratory infections, and viral panels.
• Infectious Disease Diagnostic Products Portfolio Portfolio of over 100 infectious disease diagnostic products including ICMR-approved TB detection kits and WHO-ordered point-of-care devices covering tuberculosis, HIV, hepatitis, cervical cancer (HPV), sepsis, and antimicrobial resistance.

Quantifiable outcome

• Approximately 50-51% cost reduction compared to existing molecular testing systems (₹340 vs ₹700–₹1,000 per sample)
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered minor and core.

• Mediciti Institute of Medical SciencesminorStrategic or Co-development Partner · 12 June 2026ASMS announced plans to explore potential collaboration with Mediciti Institute of Medical Sciences in Hyderabad focused on research, clinical validation, and deployment of advanced molecular diagnostic technologies. Both organizations discussed adopting Huwel Lifesciences' indigenous diagnostic solutions including tests for tuberculosis, sepsis, HPV, and antimicrobial resistance, with plans to conduct pilot programs across selected departments. The partnership aims to expand ASMS's diagnostic footprint across India and international markets.
• Stop TB PartnershipcoreStrategic or Co-development Partner · 27 March 2026Stop TB Partnership's TB REACH Wave 11 Plus initiative invested US$2.7 million across 18 projects in 12 countries to pilot three NPOC TB testing platforms including Huwel UniAmp NAT Device, with approximately 150,000 tests expected to roll out in 2026. Evidence from TB REACH-supported projects informed WHO's new policy recommendation endorsing near point-of-care nucleic acid amplification tests for tuberculosis diagnosis.
• Avio Smart Market Stack Limited (ASMS)coreStrategic or Co-development Partner · 2 March 2026ASMS (formerly Bartronics India) signed a Share Subscription-cum-Shareholders' Agreement to acquire a minority stake in Huwel Lifesciences and collaborate on business development and project execution. Under the agreement, ASMS is entitled to receive a defined share of net project revenues arising from orders secured through its institutional engagement efforts. The partnership aims to jointly scale advanced diagnostic technologies for institutional and healthcare markets across India.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Molbio Diagnostics: India-based manufacturer of Truenat, a chip-based real-time PCR platform for TB and other infectious diseases, widely deployed in India's national TB elimination programme. Directly comparable to Huwel's Quantiplus MTB FAST and UniAmp NAT as a near-point-of-care molecular TB platform targeting government and emerging-market customers.
• Cepheid (Danaher): Maker of GeneXpert MTB/RIF, the global gold-standard molecular TB cartridge system with broad emerging-market footprint. Directly competes with Huwel's molecular TB diagnostic platform on test menu, customers (national TB programmes), and POC deployment model.
• Hain Lifescience / Bruker: Developer of FluoroType MTB and other NAAT-based TB and infectious disease assays on the GenoXtract / Fluorocycler platforms. Directly competes with Huwel's NAAT products in mid-tier laboratory and reference-lab settings.
• Mylab Discovery Solutions: Indian molecular diagnostics company producing RT-PCR kits and TrueNAT-adjacent platforms for infectious disease testing including TB, HPV, and hepatitis. Comparable Indian competitor targeting similar government and clinical customers with indigenous manufacturing.

Broad incumbents

• bioMérieux: Leading molecular diagnostics player offering BIOFIRE and ARGENE molecular panels for respiratory, sepsis, and infectious diseases. Targets hospital and reference-lab customers with overlapping TB and infectious-disease menu versus Huwel's portfolio.
• QIAGEN: Provider of QIAreach and other molecular TB and infectious-disease solutions, including partnerships with Cepheid-adjacent technologies. Established global distributor relationships overlap with Huwel's emerging-market public-sector focus.
• Becton Dickinson (BD): Offers BD MAX molecular platform with TB and infectious-disease assays plus broader microbiology tools. Larger incumbent serving similar hospital and government testing customers in India and global emerging markets.
• Abbott (m-PIMA / Alinity): Broad incumbent in molecular diagnostics offering Alinity m, m-PIMA, and other platforms spanning TB, HIV, hepatitis, HPV, and AMR. Targets the same global and Indian institutional customers as Huwel but across a much larger menu and installed base.
• Roche Diagnostics: Global incumbent in molecular diagnostics (cobas Liat, cobas 6800/8800) with extensive TB and infectious-disease menus. Competes with Huwel's offerings in central-lab and select POC settings within India's public and private hospital networks.

Emerging players

• Co-Diagnostics: Developer of low-cost molecular diagnostics including Logix Smart products for infectious diseases (TB, HPV, vector-borne) targeting emerging markets. Comparable emerging player pursuing cost-disruptive molecular testing similar to Huwel's positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/huwellifesc
• Facebookfacebook.com/huwellifesciences
• LinkedInlinkedin.com/company/huwel-lifesciences-in

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Huwel Lifesciences